CS
LJPC

Candriam SCA’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Candriam SCA’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-326,300
Closed -$2.87M – 814
2019
Q3 		$2.87M Hold
326,300
– – 0.04% 427
2019
Q2 		$3M Sell
326,300
-66,000
-17% -$497K 0.04% 435
2019
Q1 		$2.52M Hold
392,300
– – 0.03% 448
2018
Q4 		$3.7M Hold
392,300
– – 0.06% 338
2018
Q3 		$7.9M Buy
392,300
+47,000
+14% +$1.23M 0.11% 224
2018
Q2 		$10.1M Sell
345,300
-2,700
-0.8% -$83.3K 0.16% 169
2018
Q1 		$10.4M Buy
348,000
+79,000
+29% +$2.55M 0.18% 156
2017
Q4 		$8.66M Buy
269,000
+88,000
+49% +$2.88M 0.15% 175
2017
Q3 		$6.29M Buy
+181,000
New +$5.82M 0.11% 229

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Candriam SCA's LJPC Position: Q4 2019 in Review

Candriam SCA sold out of La Jolla Pharmaceutical Company (LJPC) in Q4 2019, closing a stake of 326,300 shares — an estimated $2.87M sold.

Candriam SCA first reported a position in LJPC in Q3 2017 and held it in 9 quarters. The position peaked at $10.4M in Q1 2018. 77 funds tracked by Wall St. Rank hold LJPC as of Q4 2019.

  • Candriam SCA reported no remaining La Jolla Pharmaceutical Company position as of Q4 2019 after selling out during the quarter.
  • Candriam SCA sold 326,300 La Jolla Pharmaceutical Company shares in Q4 2019, an estimated $2.87M.
  • Candriam SCA first reported a position in La Jolla Pharmaceutical Company in Q3 2017 and held it in 9 quarters.
  • Candriam SCA's La Jolla Pharmaceutical Company position peaked at $10.4M in Q1 2018.
  • 77 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q4 2019.

Based on Candriam SCA's 13F filing for Q4 2019, filed 21 Jan 2020.